香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ( 股份代號 : 9939) 自願公告 GT20029 凝膠治療痤瘡中國 I I 期臨床試驗達到主要終點 本公告由開拓藥業有限公司*（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以知會本公司股東及潛在投資者有關本集團的最新進展。 茲提述本公司日期為 2024 年 6 月 17 日的自願公告，內容有關 GT20029 凝膠治療痤 瘡的中國 II 期臨床試驗（「該項 II 期臨床試驗」），其已於 2024 年 6 月 17 日完成首 例受試者入組。 本公司董事（「董事」）會（「董事會」）欣然宣佈，其自主研發的新型靶向雄激素 受體（「AR」）的蛋白降解嵌合體（「PROTAC」）化合物 GT20029 治療痤瘡的 該項 II 期臨床試驗讀出頂線數據。數據顯示，該項 II 期臨床試驗成功達到主要研究終 點，結果具有統計學顯著性及臨床意義，且有效性、安全性和藥代動力學特徵均表現 出色，並確定 III 期臨床 ...

Group 1 - The core point of the article is that 开拓药业-B (09939) is undergoing a share placement and has transferred shares from 中银国际证券 to 摩根士丹利香港证券, with a market value of 47.9072 million HKD, accounting for 5.12% of the total shares [2] - The company announced a placement of 20.673 million shares at a price of 2.08 HKD per share, representing an 18.75% discount from the previous closing price of 2.56 HKD [2] - The estimated net proceeds from the placement are approximately 40.34 million HKD, which will be used for general working capital and business purposes [2] Group 2 - Following the completion of the share placement, the shareholding of the company's co-founder, chairman, executive director, and major shareholder 童友之 will decrease from 11.19% to 10.69% [2]

Group 1 - The core point of the article is that 开拓药业-B (09939) is undergoing a share placement to raise funds for general operational purposes, with a significant discount on the share price [1] - On August 5, shareholders transferred shares worth HKD 47.9072 million from 中银国际证券 to 摩根士丹利香港证券, representing 5.12% of the total shares [1] - The company plans to place 20.673 million shares at a price of HKD 2.08 per share, which is an 18.75% discount compared to the previous closing price of HKD 2.56 [1] Group 2 - The estimated net proceeds from the share placement are approximately HKD 40.34 million, which will be used for general working capital and business operations [1] - Following the completion of the placement, the shareholding of the company's co-founder, chairman, executive director, and major shareholder 童友 will decrease from 11.19% to 10.69% [1]

Group 1 - The latest shareholder equity disclosure for Zai Lab Limited (09939) was made on August 4, 2025 [1] - Tong Youzhi reduced its holdings from 50.05 million shares to 29.37 million shares, representing a current holding percentage of 6.56%, down from 11.18% previously [2] - KT International also decreased its holdings from 47.55 million shares to 26.87 million shares, with a current holding percentage of 6.01%, down from 10.63% previously [2]

港股8月开局不利，三大指数继续承压走低，尾盘跌幅有所扩大。截止收盘，恒生指数跌1.07%或265.52 点，报24507.81点，大市交投缩减，全日成交额为2546.74亿港元；恒生国企指数跌0.88%，报8804.42 点；恒生科技指数跌1.02%，报5397.4点。全周来看，恒指累跌3.47%，国指累跌3.78%，恒科指累跌 4.94%。 东吴证券指出，往后看，市场担心海外风险上行。一是，美元资产继续上涨，或会导致全球资金减少对 中国资产的关注；二是，对等关税截止日临近，市场预期关税博弈更偏向税率"缓"+"降"。交银国际认 为，港股市场当前流动性状态仍较为充裕，估值水平保持合理，适度的市场拥挤度也为投资者提供了较 为理想的配置窗口。 蓝筹股表现 5.71港元。 1.个别快递股逆市走高。截至收盘，中通快递-W(02057)涨7.44%，报163.2港元；极兔速递-W(01519)涨 2.52%，报10.58港元。 7月29日，国家邮政局召开快递企业座谈会，就依法依规治理行业"内卷式"竞争，强化农村地区领取快 件违规收费等突出问题整治，促进行业高质量发展进行座谈交流。据现代物流报，7月17日义乌邮管局 已率先 ...

Group 1 - The Hang Seng Index fell by 0.18%, down 45 points, closing at 24,727 points, while the Hang Seng Tech Index decreased by 0.12% [1] - In the semiconductor sector, InnoSilicon became the only Chinese chip manufacturer included in NVIDIA's latest 800V architecture supplier list, leading to a more than 30% increase in InnoSilicon's stock [1] - The Ministry of Industry and Information Technology issued a special energy-saving inspection task list for the polysilicon industry, boosting the solar panel sector, with notable stock increases for companies like Kaisheng New Energy (up over 5%) and Fuyao Glass (up over 4%) [1] Group 2 - Stone Pharmaceutical Group's stock rose over 6% after announcing a more than $2 billion overseas business development deal [2] - Ruihe Smart's stock surged over 10% following a profit warning, with expected net profits for the first half of the year reaching up to 44 million yuan, marking a turnaround from losses [3] - Inspur Digital Enterprises' stock increased nearly 6%, reaching a new high, with expected net profits for the first half of the year up to 190 million yuan, supported by its parent company Inspur Group [4] Group 3 - Xirui's stock rose over 4%, reaching a new high, as institutions predict rapid growth in the private aviation market [5] - Qiniu Intelligent's stock increased by over 8%, with its AI model user base surpassing 10,000, marking a significant milestone in its AI strategy [6] - Tsugami Machine Tool's stock rose over 5%, with its Japanese division reporting a 38.1% year-on-year increase in profits for the first quarter [7] Group 4 - New Macau International Development's stock fell over 4%, with its subsidiary New Macau Borya reporting a nearly 20% year-on-year decline in net income for the second quarter [7] - Kintor Pharmaceutical's stock plummeted over 16% after the company announced a discounted placement of shares at an 18.75% discount, raising approximately 40.34 million Hong Kong dollars [7]

港股午评：恒指窄幅震荡收跌0.18% 英诺赛科午前急速拉升 金十数据8月1日讯，早间恒指小幅低开后一路围绕20天线震荡，早盘缩量明显。恒生科技指数早间一度 冲高。截至午间收盘，恒指收跌0.18%，报24727.78点，科指收跌0.12%，报5446.61点，恒指大市成交 额达1197.97亿港元。盘面上，物流板块异军突起领涨大盘，光伏、有色金属等板块造好；汽车股走势 分化，SaaS概念冲高回落转跌，石油股跌幅居前。个股方面，英诺赛科(02577.HK)午盘前急速拉升收涨 30.68%，公司成为英伟达最新800V架构供应商名单中唯一入选芯片企业；蔚来汽车(09866.HK)收涨 9.05%，公司旗下乐道L90正式上市；开拓药业(09939.HK)收跌16.41%，公司拟先旧后新配售2067.3万 股，净筹4034万港元。 ...

智通财经获悉，开拓药业-B(09939)重挫逾14%，截至发稿，跌14.06%，报2.2港元，成交额5368.85万港 元。 消息面上，开拓药业宣布，拟通过先旧后新方式配售2067.3万股股份，每股配售价2.08港元，较上一日 收盘价2.56港元折让18.75%，所得款项净额估计约为4034万港元。公司拟将认购事项所得款项净额用于 集团的一般营运资金及一般业务。紧随完成后，公司联合创始人、董事会主席、执行董事、行政总裁及 主要股东童友之于公司持股由11.19%降至10.69%。 此外，开拓药业自主研发、潜在同类首创的KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已完成 全部666名患者入组。该项关键性临床试验采用II/III期操作无缝衔接设计，II期阶段已达到主要研究终 点，结果具有统计学显着性及临床意义，且有效性和安全性均表现出色。除826外用防脱液和祛痘膏等 化妆品产品和化妆品原料外，本公司无法确保将能成功开发及最终成功销售KX-826的其他产品。本公 司股东及潜在投资者在买卖本公司股份时务请审慎行事。 本文源自智通财经网 港股异动｜开拓药业-B(09939)重挫逾14% 公司拟折让18.75 ...

Group 1 - The company, Akeso Inc. (09939), experienced a significant decline of over 14%, trading at HKD 2.2 with a transaction volume of HKD 53.6885 million [1] - Akeso announced a placement of 20.673 million shares at a price of HKD 2.08 per share, representing an 18.75% discount from the previous closing price of HKD 2.56, with estimated net proceeds of approximately HKD 40.34 million [1] - The net proceeds from the placement will be used for general working capital and business purposes, resulting in a reduction of the shareholding of the company's co-founder and major shareholder, Tong Youzhi, from 11.19% to 10.69% [1] Group 2 - The company has completed the enrollment of 666 patients in the critical Phase III clinical trial for its self-developed potential first-in-class KX-826 topical solution for hair loss [1] - The Phase II portion of the trial has met its primary endpoint with statistically significant and clinically meaningful results, demonstrating both efficacy and safety [1] - The company cannot ensure the successful development and eventual commercialization of KX-826 or other products beyond the KX-826 topical solution and acne cream [1]

智通财经APP获悉，开拓药业-B(09939)重挫逾14%，截至发稿，跌14.06%，报2.2港元，成交额5368.85 万港元。 此外，开拓药业自主研发、潜在同类首创的KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已完成 全部666名患者入组。该项关键性临床试验采用II/III期操作无缝衔接设计，II期阶段已达到主要研究终 点，结果具有统计学显着性及临床意义，且有效性和安全性均表现出色。除826外用防脱液和祛痘膏等 化妆品产品和化妆品原料外，本公司无法确保将能成功开发及最终成功销售KX-826的其他产品。本公 司股东及潜在投资者在买卖本公司股份时务请审慎行事。 消息面上，开拓药业宣布，拟通过先旧后新方式配售2067.3万股股份，每股配售价2.08港元，较上一日 收盘价2.56港元折让18.75%，所得款项净额估计约为4034万港元。公司拟将认购事项所得款项净额用于 集团的一般营运资金及一般业务。紧随完成后，公司联合创始人、董事会主席、执行董事、行政总裁及 主要股东童友之于公司持股由11.19%降至10.69%。 ...